Integrating Breast Cancer and Cardiovascular Disease Risk to Explore Decision-Making for Chemoprevention Among Racially/Ethnically Diverse Women at High Risk for Breast Cancer

$6.84M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Columbia University Health Sciences
Country	United States
Start Date	Jul 08, 2024
End Date	Jun 30, 2029
Duration	1,818 days
Number of Grantees	2
Roles	Co-Investigator; Principal Investigator
Data Source	NIH (US)
Grant ID	`10944132`

Grant Description

Women with high-risk breast lesions, such as atypical hyperplasia (AH) and lobular carcinoma in situ (LCIS), have up to a 4- to 10-fold increased risk of invasive breast cancer (BC) compared to women with non-proliferative breast disease. Chemoprevention with selective estrogen receptor modulators (SERMs) and aromatase

inhibitors (AIs) have been shown in randomized controlled trials (RCTs) to reduce BC incidence by up to 50-65% among high-risk women, with a 70-80% relative risk reduction among women with AH or LCIS. However, chemoprevention uptake remains low at